Proclara Biosciences (formerly NeuroPhage Pharmaceuticals) is a clinical‑stage biotech developing therapies based on its proprietary General Amyloid Interaction Motif (GAIM) platform, which can target multiple toxic misfolded proteins. Its lead candidate, NPT088, is in a Phase 1b clinical trial for Alzheimer’s disease. The company says GAIM enables simultaneous targeting of multiple misfolded proteins, enabling programs across neurodegenerative diseases (including Alzheimer’s and Parkinson’s) and several rare systemic amyloidoses. The recent financing will support further clinical development of NPT088 and preclinical advancement of additional molecules toward the clinic. Proclara has transitioned to a clinical‑stage company and changed its name to reflect that evolution. The company is based in Cambridge, Mass. NeuroPhage leverages novel and proprietary GAIM (General Amyloid Interaction Motif) technology to develop therapies that target multiple types of misfolded proteins. Its lead drug candidate, NPT088, is designed to simultaneously target misfolded proteins implicated in Alzheimer’s, Parkinson’s and systemic amyloidoses. The company intends to advance NPT088 into clinical studies in Alzheimer’s disease by the end of 2015 and to progress other innovative compounds for diseases of protein misfolding. NeuroPhage is led by CEO Jonathan Solomon and President and COO Franz Hefti. Financially, the company closed a $10.0M extension of its Series D private equity financing, bringing the total Series D to $27.0M; the extension was funded by new investors. NeuroPhage Pharmaceuticals develops fusion‑protein drug candidates to treat a range of neurodegenerative diseases. Its lead candidate, NPT088, is designed to target multiple misfolded protein deposits and has potential application in Alzheimer’s, Parkinson’s, Huntington’s and other rare diseases. The company’s approach is built on its GAIM (General Amyloid Interaction Motif) technology platform, which recognizes both early and aggregated forms of multiple misfolded proteins and enables simultaneous targeting of different disease‑related protein deposits. NeuroPhage is led by President and CEO Jonathan Solomon. The company completed a $17M Series D financing to advance NPT088 and potential next‑generation compounds toward clinical trials. The financing reflects the company’s near‑term focus on moving its lead program into clinical development. NeuroPhage Pharmaceuticals develops therapies targeting protein misfolding in neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its platform aims to produce broadly acting agents that reduce multiple pathogenic protein aggregates in the brain. The company is advancing a pipeline of drug candidates, including lead compound NPT002. NeuroPhage plans to use recent proceeds to support ongoing pre-IND studies for NPT002 and to advance fusion proteins for Alzheimer’s, Parkinson’s and Huntington’s diseases. The company raised equity financing to fund these development activities. NeuroPhage was founded in 2007 and is led by President and CEO Jonathan Solomon. NeuroPhage Pharmaceuticals develops a protein-disaggregation platform that targets misfolded proteins for the treatment and prevention of neurodegenerative diseases. The company is advancing a novel therapeutic in development for Alzheimer’s disease and has received Michael J. Fox Foundation funding for Parkinson’s disease research. Proceeds from its latest financing will be used to advance the Alzheimer’s program. Since inception the company has raised $28.6m in equity capital. NeuroPhage was founded in 2007 by Jonathan Solomon, MBA, and is based in Cambridge, MA.

Total raised

$102M

Funding rounds

6

Latest round

Series E

Latest activity

Sep 2016